Sugi Predict

Sugi Predict / Compounds / SCHEMBL2882464

SCHEMBL2882464

SCHEMBL2882464

CNc1ncnc2ccc(/C=C3/SC(=N)NC3=O)cc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.50
▸ KMT2A Q03164 2/20 0.50
▸ POLB P06746 2/20 0.47
▸ MRE11 P49959 1/20 0.47
▸ CLK1 P49759 4/20 0.45
▸ DYRK1A Q13627 4/20 0.45
▸ DYRK1B Q9Y463 3/20 0.45
▸ CLK2 P49760 2/20 0.45
▸ CLK3 P49761 1/20 0.45
▸ XDH P47989 3/20 0.45
▸ PIK3CD O00329 3/20 0.44
▸ CSNK2A2 P19784 3/20 0.44
▸ PIK3CA P42336 3/20 0.44
▸ PIK3CG P48736 3/20 0.44
▸ PIK3CB P42338 2/20 0.44
▸ MTOR P42345 2/20 0.44
▸ CSNK2B P67870 2/20 0.44
▸ CSNK2A1 P68400 2/20 0.44
▸ DYRK2 Q92630 2/20 0.44
▸ NPC1 O15118 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2882465 1.00 MEN1 (0.50) MEN1KMT2APOLBMRE11CLK1
SCHEMBL12975478 1.00 MEN1 (0.50) MEN1KMT2APOLBMRE11CLK1
SCHEMBL12975471 0.90 CISD1 (0.56) CLK1DYRK1ADYRK1BCLK2PIK3CD
SCHEMBL2877564 0.90 CISD1 (0.56) CLK1DYRK1ADYRK1BCLK2PIK3CD
SCHEMBL2877560 0.90 CISD1 (0.56) CLK1DYRK1ADYRK1BCLK2PIK3CD
SCHEMBL2882012 0.82 PIP4K2A (0.48) MEN1KMT2APOLBMRE11CLK1
SCHEMBL12975484 0.82 PIP4K2A (0.48) MEN1KMT2APOLBMRE11CLK1
SCHEMBL2882014 0.82 PIP4K2A (0.48) MEN1KMT2APOLBMRE11CLK1
SCHEMBL4636794 0.82 PIM1 (0.48) MEN1KMT2ACLK1DYRK1ADYRK1B
SCHEMBL4636797 0.82 PIM1 (0.48) MEN1KMT2ACLK1DYRK1ADYRK1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7846925-B2 Azolidinone-vinyl fused-benzene derivatives MERCK SERONO SA (CH) 2010-12-07 — — US claimed
US-20090042773-A1 P13 kinase gamma inhibitors for the treatment of anaemia MERCK SERONO SA (CH) 2009-02-12 — — US claimed
EP-1807075-A2 PI3 KINASE GAMMA INHIBITORS FOR THE TREATMENT OF ANAEMIA Applied Research Systems ARS Holding N.V. (AN) 2007-07-18 — — EP claimed
US-20060122176-A1 Azolidinone-vinyl fused-benzene derivatives MERCK SERONO SA (CH) 2006-06-08 — — US claimed
WO-2006040318-A2 PI3 KINASE GAMMA INHIBITORS FOR THE TREATMENT OF ANAEMIA APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2006-04-20 — — WO claimed
US-20050222225-A1 Use of compounds for increasing spermatozoa motility APPLIED RESEARCH SYSTEMS ARS HOLDING NV (NL) 2005-10-06 — — US claimed
EP-1549644-A1 AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES Applied Research Systems ARS Holding N.V. (AN) 2005-07-06 — — EP claimed
EP-1531813-A1 USE OF COMPOUNDS FOR INCREASING SPERMATOZOA MOTILITY Applied Research Systems ARS Holding N.V. (AN) 2005-05-25 — — EP claimed
WO-2004007491-A1 AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2004-01-22 — — WO claimed
WO-2004006916-A1 USE OF COMPOUNDS FOR INCREASING SPERMATOZOA MOTILITY APPLIED RESEARCH SYSTEMS ARS HOLDING NV (AN) 2004-01-22 — — WO claimed
US-7846925-B2 Azolidinone-vinyl fused-benzene derivatives MERCK SERONO SA (CH) 2010-12-07 — — US disclosed
US-20090306069-A1 AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES LABORATOIRES SERONO S.A. (CH) 2009-12-10 — — US disclosed
US-20080306057-A1 P13K Inhibitors for the Treatment of Endometriosis LABORATORIES SERONO SA (CH) 2008-12-11 — — US disclosed
US-20060122176-A1 Azolidinone-vinyl fused-benzene derivatives MERCK SERONO SA (CH) 2006-06-08 — — US disclosed
US-20050222225-A1 Use of compounds for increasing spermatozoa motility APPLIED RESEARCH SYSTEMS ARS HOLDING NV (NL) 2005-10-06 — — US disclosed
EP-1549644-A1 AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES Applied Research Systems ARS Holding N.V. (AN) 2005-07-06 — — EP disclosed
EP-1531813-A1 USE OF COMPOUNDS FOR INCREASING SPERMATOZOA MOTILITY Applied Research Systems ARS Holding N.V. (AN) 2005-05-25 — — EP disclosed
WO-2004007491-A1 AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2004-01-22 — — WO disclosed
WO-2004006916-A1 USE OF COMPOUNDS FOR INCREASING SPERMATOZOA MOTILITY APPLIED RESEARCH SYSTEMS ARS HOLDING NV (AN) 2004-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306069-A1 AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES ZAP70, BRCA1, ZYX MEN1 1495/4885KMT2A 3006/4885POLB 3004/4885
US-20090042773-A1 P13 kinase gamma inhibitors for the treatment of anaemia PDPK1, PRKD3, PRKD1 MEN1 2366/4885KMT2A 1230/4885POLB 1667/4885
US-20050222225-A1 Use of compounds for increasing spermatozoa motility CATSPER1, PI4KB, MAN2B2 MEN1 3768/4885KMT2A 2969/4885POLB 1875/4885
US-20080306057-A1 P13K Inhibitors for the Treatment of Endometriosis PDPK1, PIK3R4, MAP3K3 MEN1 1758/4885KMT2A 603/4885POLB 3358/4885
US-20060122176-A1 Azolidinone-vinyl fused-benzene derivatives BRCA1, ZAP70, F13B MEN1 1543/4885KMT2A 3104/4885POLB 3117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.